Global Retirement Partners LLC Has $1.12 Million Stock Position in Natera, Inc. $NTRA

Global Retirement Partners LLC raised its holdings in Natera, Inc. (NASDAQ:NTRA) by 432.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,894 shares of the medical research company’s stock after buying an additional 3,974 shares during the quarter. Global Retirement Partners LLC’s holdings in Natera were worth $1,121,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NTRA. Horizon Investments LLC bought a new stake in Natera in the third quarter valued at $32,000. Flagship Harbor Advisors LLC acquired a new position in shares of Natera during the fourth quarter valued at about $41,000. Sound Income Strategies LLC boosted its position in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in shares of Natera in the 4th quarter valued at about $62,000. Finally, AXS Investments LLC acquired a new stake in shares of Natera in the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In related news, CFO Michael Burkes Brophy sold 482 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer owned 57,496 shares of the company’s stock, valued at approximately $12,102,333.04. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 902 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $206.16, for a total transaction of $185,956.32. Following the transaction, the chief executive officer directly owned 149,867 shares of the company’s stock, valued at approximately $30,896,580.72. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,266 shares of company stock valued at $7,747,808 in the last three months. 5.63% of the stock is owned by company insiders.

Natera Stock Performance

Shares of Natera stock opened at $203.19 on Tuesday. The business’s fifty day simple moving average is $201.17 and its 200 day simple moving average is $215.49. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The firm has a market capitalization of $29.10 billion, a P/E ratio of -124.66 and a beta of 1.57.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same quarter in the prior year, the company earned ($0.41) EPS. Analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. William Blair assumed coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Evercore restated an “outperform” rating and set a $270.00 price objective on shares of Natera in a report on Friday, May 8th. Finally, Morgan Stanley dropped their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.